Novomics Co., Ltd. designs and develops genetic molecular diagnostics solutions. The company offers nProfiler1 Expansion Stomach Cancer Assay to analyze the gene expression profiles of stage II-III gastric cancer. It also provides nProfiler 2, a cancer variant assay; AI assisted digital pathology and auto sampling system; nProfiler, a breast cancer assay; nProfiler, a colon cancer assay; nProfiler, a rectal cancer assay; and nProfiler, a cOVID-19 detection kit. The company was formerly known as Novomics Meditech Co., Ltd. and changed its name to Novomics Co., Ltd. in July 2015. Novomics Co., Ltd. was founded in 2010 and is based in Seoul, South Korea.
Metrics to compare | 283100 | Peers Peers - average of corresponding metrics from companies closely matching 283100: | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship283100PeersSector |
---|---|---|---|---|
P/E Ratio | 0.0x | 0.0x | −0.5x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 0.0x | 0.0x | 2.6x | |
Price / LTM Sales | 0.0x | 0.0x | 3.1x | |
Upside (Analyst Target) | 0.0% | 0.0% | 47.8% | |
Fair Value Upside | Unlock | 0.0% | 6.9% | Unlock |